CasInvent Pharma
Entity

  • CasInvent Pharma

    Created in 2020
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    289

  • Activities

    deeptech healthtech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    Kamenice 771/34, 625 00 Brno-Brno-Bohunice, Czechia

    Brno

    Czechia

  • Employees

    Scale: 2-10

    Estimated: 7

  • Engaged corporates

    0
    0 0

  • Added in Motherbase

    5 months, 2 weeks ago
Description
  • Value proposition

    Novel Treatment of Leukemias, Lymphomas and Solid Tumors with Highly Potent and Selective Inhibitors of CK1 Kinases

    The mission of CasInvent Pharma is to bring new therapeutic options for the treatment of selected leukemias to market. We are developing highly selective small molecule inhibitors of casein kinase I (CK1), and our main development program is focused on the identification of new drugs for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).

    CasInvent Pharma was established in 2020 as a spin-off company of Masaryk University in cooperation with the investment partner i&i Prague.

  • CASINVENT - Highly Potent and Selective Inhibitors of CK1 Kinases

    Highly Potent and Selective Inhibitors of CK1 Kinases for the Treatment of Leukaemias, Lymphomas and Solid Tumors

    • https://www.casinvent.com/
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Last news
Show all articles
Social network dynamics